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ABSTRACT 
 
Although the endothelium has a number of important functions, the term endothelial 
dysfunction is commonly used to describe impairment in its vasodilatory capacity. It is 
increasingly recognised that this is related to hypertension, although whether it predates 
essential hypertension or is a consequence of it is still unknown. In this review we explore the 
mechanisms of endothelial dysfunction in essential hypertension, its prognostic significance 
and methods of pharmacological reversal. 
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CONDENSED ABSTRACT 
 
Endothelial dysfunction is prevalent in hypertension and has a recognised association with the 
condition. In this article we review the pathophysiology of endothelial dysfunction in human 
essential hypertension, its prognostic significance and methods of pharmacological reversal.  
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Essential hypertension is a worldwide epidemic, with approximately 20% of the world’s 
population estimated to have a blood pressure greater than 140/90mmHg, and accounting for 
around 10% of worldwide healthcare costs1, 2. Due to its position as the leading risk factor for 
death worldwide, there is an increased drive towards its prevention3. Much of the adverse 
cardiovascular risk associated with hypertension is derived from its contribution to 
atherosclerosis, despite the two being distinct pathophysiological processes4.  
 
Intuitively, the shared link between the two processes is the endothelium. Initially thought of 
as being a simple layer of cells in the vasculature separating blood from the interstitial space, 
it is now recognised as a key regulator of vascular health. Abnormalities in normal 
endothelial function are now recognised as a key part of both the atherosclerotic and 
hypertensive disease processes, sharing many common features. 
 
Although the endothelium has a number of functions, the term “endothelial dysfunction” is 
usually used to refer to abnormalities in its vasodilatory capacity, and this is what we shall 
refer to in this paper. In this review we will discuss endothelial dysfunction, its links with 
hypertension and prognostic significance, before discussing treatment options and future 
direction. 
 
What is Endothelial Dysfunction? 
The endothelium responds to a number of endocrine, paracrine and autocrine signals to 
regulate these functions. The first evidence of this was described by Furchgott and Zawadzki 
who identified that the large blood vessels of rabbits only relaxed in response to acetylcholine 
if the endothelium was intact due to what they called endothelium-derived relaxing factor – 
which we now know as nitric oxide (NO)5. In fact, the endothelium releases a number of 
vasodilating and vasoconstricting factors with a local paracrine action. However, the healthy 
endothelium has a naturally vasodilated resting state, mainly due to the action of NO. NO is 
produced by the endothelium from L-arginine via the enzyme nitric oxide synthase in 
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response to numerous factors including mechanical shear stress. NO passes into the 
underlying smooth muscle by diffusion, stimulating guanylate cyclase to cause increased 
cyclic GMP production and thus causing vasodilation6. NO has a number of vascular 
protective functions, impairment of which could have damaging cardiovascular 
consequences. It is a strong inhibitor of platelet aggregation and adhesion, giving it anti-
atherosclerotic properties. It also inhibits adhesion to leukocytes to the vessel wall and 
proliferation of vascular smooth muscle cells7. These features give the endothelium an 
important role in prevention of atherosclerosis development. 
 
Any damage to the endothelium can cause impairment of its normal function i.e. endothelial 
dysfunction. This process is characterised by an imbalance in endothelium-dependent 
vasodilation and vasoconstriction and can occur by one of 3 methods.  
 
1. Reduced production of NO; for example caused by reduced endothelial nitric oxide 
synthase (eNOS) activity due to asymmetric dimethylarginine (ADMA), a 
competitive inhibitor of eNOS8. 
2. Reduced availability of NO; caused by reactive oxygen species (ROS) which convert 
NO to peroxynitrite which does not cause vasodilatation.9 
3. Antagonism of NO by endothelium derived contracting factors.10 
 
Assessment of Endothelial Function 
Clinically endothelial function can be measured both invasively and non-invasively, and these 
have recently been reviewed in detail by Flammer et al.11 We will briefly describe some of 
these techniques.  
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Invasive Assessment of Endothelial Function 
Invasive measurement of endothelial function can be conducted in the coronary arteries by 
quantitative angiography. This can be supplemented by intravascular ultrasound for more 
detailed assessment of the vasculature and intracoronary flow.12, 13  
 
Venous occlusion plethysmography is another commonly used technique for assessment of 
endothelial function. The technique can theoretically be performed in any vascular bed, but is 
most commonly performed in the forearm circulation, by cannulation of the brachial artery.14 
Venous return in the forearm is prevented by inflation of a cuff to above venous pressure but 
below diastolic arterial pressure (e.g. 40mmHg) with the forearm placed above the heart. The 
cuff is then deflated. A further cuff is inflated at the wrist to exclude the effects of the hand 
circulation. Changes in blood flow in the forearm can be measured using a plethysmograph. 
The concept relies on the concept that if (venous) blood flow out of the forearm is restricted 
but (arterial) inflow is maintained, the forearm swells at a rate in proportion to blood flow. As 
well as using plethysmography, ultrasound can also be used to measure arterial blood flow 
velocity and diameter (and hence flow). 
 
Endothelial function can also be measured in the microvasculature. This is usually conducted 
by obtaining subcutaneous tissue biopsies, dissecting out small vessels and measuring 
function using micromyography (therefore it is an ex-vivo method to measure endothelial 
function).15 There have been varying results in studies correlating microvascular endothelial 
dysfunction and larger artery dysfunction, although this might be expected in different 
vascular beds.16-18 
 
Non-Invasive Assessment of Endothelial Function 
The commonest non-invasive technique for evaluation of endothelial function currently in use 
involves brachial ultrasound during reactive hyperemia assessing flow mediated dilation 
(FMD). This involves interruption of blood flow in a peripheral artery (most commonly 
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brachial) using a cuff to cause temporary ischemia. Release of the cuff causes an increase in 
blood flow and shear stress, leading to NO release and vasodilatation. The change in diameter 
of the blood vessel can be measured by ultrasound and is directly related to NO 
bioavailability, this providing a measure of endothelial function.19 This technique is 
particularly attractive as it is easy to repeat in patients, however there is still some variation 
between centres regarding image acquisition, for example in the time when measurements are 
obtained after cuff release so there still needs to be some standardization of the technique, 
though there have been attempts to do that.20, 21 Recently, FMD has shown good, reproducible 
results in multi-centre studies when rigorous methodology is used, perhaps suggesting that it 
will soon be able to be utilised in large prospective population studies as an outcome 
measure.22, 23 In a seven-centre study by Ghiadoni et al, the authors evaluated 135 adult 
healthy volunteers to assess reproducibility of FMD using a standardized protocol at 3 
timepoints (baseline, 1 hour after baseline and 30 days after). They found that the technique 
was extremely reproducible across all sites, indicating that FMD could be used as a valid trial 
endpoint.22 These findings were extended in a further multi-centre study by Charakida et al 
who also evaluated patients up to 9 months after baseline FMD evaluation, and again the 
technique showed excellent reproducibility.23 
 
Peripheral artery tonometry (PAT) is a technique that non-invasive assessment of vasomotor 
function by plethysmographically measuring changes in the fingertip pulse (most commonly) 
as a surrogate for arterial tone. Again, the endothelium-dependent response can be ascertained 
by reactive hyperaemia following arterial cuff occlusion.24 
 
The cold pressor test was initially described in the 1930s by Hines and Brown.25 To 
summarise, the test involves the immersion of the patient’s hand into a bowl of ice-cold 
water, which causes increased sympathetic activity, leading to peripheral vasodilatation and a 
rise in blood pressure. Additionally, this also causes coronary vasodilatation and an increase 
in myocardial blood flow in healthy patients.26 Therefore, using this technique, vascular 
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endothelial function can be assessed in a number of ways. Non-invasive methods include 
measures of blood pressure, peripheral arterial diameter,27 echocardiographic coronary artery 
diameter28 and techniques to evaluate myocardial blood flow such as PET26. Additionally, 
invasive techniques can be used to assess changes in coronary artery size during coronary 
artery catheterisation.29  
 
More recently, laser Doppler has been utilised to measure endothelial function. This 
technique allows for non-invasive measurement of the microvasculature of the skin by 
assessing skin blood flow.30-32 This technique uses the backscatter provided by moving 
erythrocytes when they reflect a laser signal scanned across the skin. The erythrocytes reflect 
the signal back at a frequency proportional to their velocity hence blood flow can be 
measured.  
 
What is the Evidence for Endothelial Dysfunction in Hypertension – Cause or Effect? 
Demonstration of impaired endothelial dysfunction in hypertensive patients in the forearm 
resistance vessels was first reported, almost simultaneously in the early 90s, by Panza et al33 
and Linder et al.34 In the study by Panza et al, the authors studied changes in forearm blood 
flow in 18 hypertensive patients and 18 normotensive control subjects in response to 
acetylcholine and found that this response was impaired in the hypertensive patients. Linder 
et al evaluated 14 stable outpatients with essential hypertension (compared to 20 controls) and 
also found that the response to acetylcholine was blunted in hypertensives compared to 
controls. These findings have since been confirmed in patients with both essential and 
secondary hypertension.35-38  
 
For a long time it has been thought that hypertension caused endothelial dysfunction. Since 
the first study by Panza et al33 there have been numerous attempts to identify the mechanisms 
linking hypertension and endothelial dysfunction, however they are still not yet completely 
understood. There is a significant genetic component to the development of hypertension, and 
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Taddei et al used this to try and identify a common pathway in the adult offspring of 
hypertensive patients39. In this study the authors found that the normotensive offspring of 
hypertensive patients had significantly impaired response to ACh in comparison to 
normotensive offspring of normotensive patients due to a defect in the L-arginine-NO 
pathway. Further evidence of a link between endothelial dysfunction and hypertension was 
obtained from the Framingham data40. In this study systolic blood pressure was significantly 
inversely correlated with FMD, although the design of the study did not allow for 
determination of causation. Another study found that the presence of elevated blood pressure 
in a cohort of Finnish teenagers was predictive of impaired FMD after 21 years of follow-
up41. Transient experimentally-induced hypertension has been shown to cause acute 
impairment of endothelial function in normotensive individuals42.  
 
The mechanism of by which hypertension might cause endothelial dysfunction has been 
evaluated in various studies which have proposed a number of pathways, although many are 
in animals and of course caution is advised in extrapolation to human studies. Increased blood 
pressure causes an increase in superoxide production and a decrease in NO bioavailability9, 43. 
A second mechanism involves the renin-angiotensin system. Angiotensin-converting enzyme 
(ACE) acts on the endothelium converting angiotensin I to angiotensin II. This causes 
vasoconstriction and also promotes production of endothelin, another potent vasoconstrictor. 
An increase in both of these vasoactive substances manifests as endothelial dysfunction44. 
However, the adverse prognostic effects of angiotensin II are not purely due to 
vasoconstriction. Indeed, hypertensive patients tend to have similar levels of plasma 
angiotensin to normotensives45. In fact, angiotensin II also stimulates production of 
superoxide which leads to peroxynitrite formation. Peroxynitrite oxidizes arachidonic acid to 
form isoprostane, a potent vasoconstrictor. 
 
The hypothesis that hypertension is a consequence of endothelial dysfunction has also been 
explored. A dysfunctional endothelium with poor vasomotor function would be in a state of 
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predominant vasoconstriction leading to a higher resting blood pressure. In one of the largest 
studies to date, Rossi et al examined 952 post-menopausal normotensive women and found 
that the risk of development of hypertension over the 3.6-year follow-up period was 
significantly higher in patients with low FMD compared with those with the highest at 
baseline.46 This was however a study in a low-risk population in women and it is not clear if 
these results can be extrapolated to higher risk populations and males. Another recent study 
by Weil et al suggested that individuals with “pre-hypertension” (defined as BP 120-139/80-
89) also had impaired endothelium-dependent vasodilation, which the authors speculated 
might lead to the development of hypertension.47 
 
It is likely that the relationship between endothelial dysfunction and hypertension is not 
sequential, but rather a cyclical one. Worsening in one may lead to worsening in the other, in 
a “vicious cycle” effect. Therefore, it could be important to establish its prognostic 
significance, if any, and consider treatment options. 
 
The Prognostic Significance of Endothelial Dysfunction in Hypertension 
Endothelial dysfunction has been shown to be an adverse prognostic indicator in several 
studies, for example in patients with coronary artery disease48, 49, heart failure50, 51 and 
peripheral vascular disease52. Fewer studies have been conducted specifically in hypertension 
however. One of the earliest studies investigating the prognostic value of endothelial 
dysfunction in hypertension was carried out by Perticone et al.53 In this study the authors 
examined 225 patients with untreated hypertension and found that the only independent 
predictors of future cardiovascular events were mean 24-hour blood pressure and endothelial 
dysfunction measured by forearm blood flow response using FMD. Hypertensive patients 
who have shown an improvement in endothelial function following intensive antihypertensive 
treatment also appear to have a better outcome than those in whom endothelial function does 
not improve.54 Despite these promising early studies there have been no other large trials 
replicating these results. Some doubts about the generalizability of the study by Perticone et 
 11 
al. could be raised, particularly regarding the surprisingly high event rate for what would be 
expected to be a low-risk population (4.9%/year). Indeed, conflicting results to these have 
been found in one smaller study.55 All in all, it has not yet been established that endothelial 
dysfunction can be used as a predictor of adverse cardiovascular outcome in hypertensive 
patients, despite the evidence for its existence.  
 
Pharmacological Reversal of Endothelial Dysfunction in Hypertension 
Given the potential prognostic significance of endothelial dysfunction in hypertension, many 
studies have been conducted to improve endothelial function in this group of patients. The 
obvious starting point is with anti-hypertensive therapy. All of the mainstays of 
antihypertensive therapy have been extensively studied.  
 
The Renin-Angiotensin-Aldosterone System 
The majority of work has been conducted in drugs affecting the renin-angiotensin-aldosterone 
system. Angiotensin II stimulates angiotensin type 1 receptors (AT1) to mediate arteriolar 
vasoconstriction and remodelling, superoxide anion production, renal sodium reabsorption, 
aldosterone secretion and endothelin (ET-1) release.56 Many of these actions affect the 
vascular endothelium adversely. On the other hand stimulation of the angiotensin type 2 
(AT2) receptor by angiotensin has mainly opposing actions to those of AT1 stimulation and 
recently has been shown to contribute to endothelial NO release.57 Hence, AT1 receptor 
blockade could improve NO bioactivity. 
 
Angiotensin II can be reduced by angiotensin converting enzyme inhibitors which also 
increase both tissue and plasma bradykinin by inhibiting kininase II.58 By stimulating the B2 
receptors, bradykinin mediates the release of NO, prostacyclin and the endothelial 
hyperpolarizing factor (EDHF); agents that produce vasodilation.59-61 ACE-Is (angiotensin 
converting enzyme inhibitors) and ARBs (angiotensin receptor blockers) are among the first-
line therapies for hypertension.62 Two large studies have investigated the effects of ACE-Is 
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and ARBs in the coronary and forearm vasculature (TREND, BANFF) respectively in 
patients with atherosclerosis, showing improvement in endothelial function.63, 64 Several 
studies have confirmed this beneficial effect in hypertensive patients. Two independent long-
term studies evaluating respectively the vascular responses to cilazapril and lisinopril on 
subcutaneous arteries (small resistance vessels) in essential hypertensives showed a 
considerable improvement in stimulated NO release following prolonged treatment with these 
agents.65, 66 Similar results were obtained in the coronary microcirculation of hypertensive 
patients with ACE-I. Antony et al showed that intravenous perindoprilat (the active 
metabolite of perindopril) restored the cold pressor test response and flow-mediated coronary 
artery vasodilation in 10 patients with untreated (newly diagnosed) essential hypertension.67.  
Taddei et al have reported that 1 year of treatment with lisinopril improved endothelium-
dependent and independent vasodilatation in forearm vasculature of hypertensives.68 Several 
other studies also report improvement in endothelial function following ACE inhibition.69-73 
However, there have also been studies have showing conflicting results.74, 75 
 
There are also reports of the beneficial effects of ARBs on endothelial function. Schiffrin et al 
reported that one year of treatment with losartan improved both functional and structural 
properties of small resistance (subcutaneous) arteries in hypertensive patients.76 Ghiadoni et 
al found that 1 year of treatment with candesartan improved stimulated NO release, but this 
was accompanied by a concomitant endothelium-independent improvement suggesting an 
alteration in vascular smooth muscle cell responsiveness.77 Tzemos et al also found that 
valsartan mediated an improvement in endothelial function through both NO-dependent and 
independent pathways.78 This is slightly contrary to a study by Klingbeil et al who found that 
while valsartan causes an increase in nitric oxide production in hypertensives there was no 
improvement in ACh mediated vasodilatation.79 The authors postulated that the changes in 
ACh mediated vasodilatation may take longer to occur in hypertension and therefore require a 
longer period of treatment (the patients in this study were treated for 6 weeks as opposed to 
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16 weeks in the study by Tzemos et al.). Further studies have also shown beneficial effects on 
endothelial function with ARBs.80 
 
In summary, blocking the renin-angiotensin-aldosterone system either at the conversion from 
angiotensin I to II or at the angiotensin II receptor level may favourably affect NO bioactivity. 
It is likely that in the forearm microcirculation the tissue renin-angiotensin system is the 
predominant generator of angiotensin II hence only ACE-Is with high tissue penetration 
(enough to block the tissue renin-angiotensin system) are likely to be effective 63, 81. In a sub-
analysis of the recent EUROPA study (examining the beneficial effects of ACE-inhibition in 
patients with stable coronary artery disease), perindopril appeared to increase expression and 
activity of eNOS by 19% and 27% respectively, as well as a significant reduction in plasma 
levels of angiotensin II, tumour necrosis factor-α and an increase in bradykinin, nitrate and 
nitrite 82. 
 
In summary, it would appear that of ACEIs and ARBs overall have beneficial effects on 
endothelial function.83-87  
 
Spironolactone and eplerenone, mineralocorticoid receptor antagonists, have received much 
attention recently. They are recommended as 3rd or 4th line therapy in hypertension.62 They 
have been reported to improve NO bioactivity in patients with heart failure.88 The 
mechanism(s) by which aldosterone impairs endothelial function is unclear. Aldosterone it is 
known to enhance vascular responsiveness to pressor agents such as norepinephrine and 
angiotensin II even before the systemic blood pressure begins to increase.89 In patients with 
secondary hypertension due to aldosterone producing adrenal adenomas, surgical excision of 
these tumours removed the excess circulating aldosterone resulting in a normalised 
acetylcholine vascular response, i.e. improved endothelial function and BP control.90 
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While there have been several animal studies showing beneficial effects of aldosterone 
blockade91-94, there have been fewer in humans and results have been mixed. Savoia et al 95 
conducted a randomised controlled trial comparing eplerenone to atenolol in 16 patients for 1 
year and concluded that eplerenone treatment was associated with reduced arterial stiffness, 
decreased collagen/elastin ratio, and a reduction in circulating inflammatory mediators. While 
the study by Savoia et al and one by Yamanari et al96 did not show that this improvement in 
endothelial function with aldosterone antagonists translated to humans, a more recent study 
by Fujimura did find an improvement in FMD with eplerenone97. A further study in 320 post-
menopausal women with hypertension by Rossi et al reported that use of aldosterone receptor 
antagonists (in conjunction with routine anti-hypertensive therapy) was the only drug class 
independently associated with improvement in FMD after 6 months.98 
 
Aliskiren, a novel direct renin inhibitor, has been recently studied in humans by Virdis in a 
comparative study against ramipril.99  Aliskiren produced a significantly greater reduction in 
augmentation index and improved the vasodilatory response to acetylcholine, however blood 
pressure and pulse wave velocity reduction was the same in both groups. Dorresteijn et al also 
suggest that aliskiren may provide benefits in endothelial function in comparison to 
moxonidine or hydrochlorothiazide.100 These results may provide interesting directions for 
further research, although aliskiren cannot as yet be recommended as anti-hypertensive 
therapy. 
 
Dihydropyridine Calcium Channel Blockers 
These are also recommended as first-line antihypertensive therapies.62 Calcium channel 
blockers (CCBs) have been shown to have a beneficial effect on nitric oxide bioactivity in 
coronary, forearm and resistance (subcutaneous) vascular beds.71 Perticone et al showed that 
oral isradipine also improved both stimulated (ACh-induced) and basal NO release in 
hypertension.101 Taddei et al demonstrated contrasting effects on the endothelium with acute 
and chronic administration of a highly lipophilic CCB, lacidipine.102 This group showed that 
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intra-arterial lacidipine did not significantly affect acute NO bioactivity, but chronic (2 and 8 
months) oral treatment with this agent significantly increased vasodilatation in response to 
acetylcholine and bradykinin compared to baseline. Interestingly, this improvement in 
endothelial function persisted 2 weeks after drug withdrawal, despite the patients returning to 
hypertensive state. This suggests that improvement in endothelial function may be separate to 
blood pressure control, or that the effects of medications on each may have different 
durations. Similar improvements in endothelial function have been seen in other studies 
also.103, 104 
 
The mechanism by which CCBs improve endothelial dysfunction is unclear, although several 
mechanisms have been postulated. CCBs act directly on voltage dependent L-type calcium 
channels found on the vascular smooth muscle cells. Blockade of these channels reduces the 
influx of extracellular calcium into the sarcoplasmic reticulum facilitating vascular smooth 
muscle cell relaxation. However, endothelial cells are devoid of these receptors for calcium 
channel blockers to act on. In the coronary microcirculation the addition of a calcium channel 
blocker appears to indirectly facilitate an increase in intracellular smooth muscle cell cGMP, 
which is the second messenger of NO and mediates its vasodilation. Therefore, as expected an 
increase in intracellular cGMP with calcium channel blockers enhances both endothelium 
dependent and independent vasodilation.105, 106 This has been confirmed with both 
dihydropyridine and non-dihydropyridine calcium channel blockers. In contrast, in the 
forearm microcirculation, calcium channel blockers do not appear to influence the NO-
independent pathway whenever exogenous organic sources of NO such as nitrates 107are 
present.  
 
Two additional mechanisms have been described to explain the effects of calcium channel 
blockers in the forearm circulation. The first explanation is that most calcium channel 
blockers have antioxidant activities, reducing production of superoxide anions.88, 89 The 
second explanation involves a reduction in endothelin-1 release by calcium channel blockers. 
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Normally, there is a balance between vasoconstrictive and vasodilating substances in the 
vasculature but in hypertension, the bioavailability of endothelin might be increased in 
parallel with a reduction in NO bioactivity. Cardillo et al have recently shown that in patients 
with essential hypertension, the increased endothelin activity is partly responsible for the 
increased vascular tone.108 It has been shown that calcium channel blockers improve NO 
bioactivity by reducing endothelin release.100, 101 Hence, in a model where vasoconstrictive 
activity is increased, such as hypertension, a reduction of endothelin release would improve 
NO bioactivity. CCBs may also improve other aspects of endothelial dysfunction, e.g. 
reducing tissue plasminogen activator activity, thus reducing thrombogenic risk by decreasing 
platelet activation.109 
 
Diuretics and Beta-blockers 
Diuretics (specifically thiazides) are mainstays of anti-hypertensive therapy, and although 
beta-blockers are now no longer first-line for hypertension, they remain widely prescribed in 
hypertensive patients, particularly in those with concomitant conditions such as angina. 
However, despite the efficacy of both classes of drugs in improving overall prognosis in 
hypertension, neither has been consistently shown to significantly improve endothelial 
function.73, 76, 110-113 One exception is nebivolol, a highly selective β1-blocker that has been 
shown to improve endothelial dysfunction both in vivo and vitro.114, 115 Dawes et al reported 
that acute intra-arterial administration of nebivolol improved forearm vasculature NO 
bioactivity in hypertensive patients. Although the mechanism by which nebivolol improves 
endothelial function in hypertension is not yet fully elucidated a putative pharmacological 
cross-reactivity between serotonin and β-receptors might potentially explain these vascular 
effects.116, 117 A possible antioxidant property of nebivolol has been suggested as an additional 
factor increasing NO-bioactivity or even a reduction in endothelin (ET-1) release.118, 119 The 
beneficial effects of nebivolol on the endothelium were confirmed in humans by Tzemos et 
al.120 In a double-blind crossover trial, 12 hypertensive patients were given 8 weeks of 
treatment with bendroflumethiazide plus atenolol or nebivolol (and then switched to the other 
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group). With both treatments the blood pressure reduction was the same, however there was a 
significant increase in both forearm vasodilatory response to acetylcholine and the 
vasoconstrictor response to L-NMMA, suggesting that there may be a beneficial effect of 
nebivolol beyond blood pressure reduction. The endothelial effects of nebivolol are unique 
amongst beta-blockers and have been replicated in other studies.121, 122 Recent work by Vitale 
et al has suggested that nebivolol in combination with hydrochlorthiazide might at least be 
non-inferior to irbesartan with hydrochlorthiazide, perhaps giving some hope to beta-blockers 
in hypertension.123 Indeed, a recent meta-analysis of 1,273 patients from 16 studies by Peller 
et al. on the effects of beta-blockers on endothelial function in various groups of patients did 
shown some benefit, however the study did include somewhat homogenous groups of 
patients.124 The authors did find, consistent with studies in hypertension, that the best 
improvement in endothelial function was seen with 3rd generation beta-blockers such as 
nebivolol. 
 
There have been some small studies suggesting that thiazide (and thiazide-like) diuretics 
might improve endothelial function. Some studies have shown that indapamide may also 
improve endothelial function in hypertensive patients when used in combination with ACE 
inhibitors.125, 126 Chlortalidone has also been shown to improve endothelial dysfunction in 
hypertensive patients.127 The beneficial effects shown in these relatively small studies have 
yet to be confirmed in larger trials, particularly studies focussing on cardiovascular outcomes. 
 
Endothelin Receptor Antagonists 
Endothelin 1 (ET-1) acting through the ETA receptor is a potent vasoconstrictor that also 
promotes vascular smooth muscle cell proliferation.128, 129 Its expression in the vessel wall is 
promoted by ATII, and its vasoconstrictive effect appears to be enhanced in hypertensives.107, 
130, 131 However, the plasma levels of ET-1 have not been consistently found to be raised in 
hypertension.132, 133 Nonetheless, ET-1 is released abluminally rather luminally, hence its 
plasma levels may not necessarily reflect its activity.134 Increased ET-1 activity has been 
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found in salt-sensitive hypertension.135, 136 In human hypertension, Cardillo et al have shown 
that forearm intrabrachial administration of both selective and non-selective endothelin 
receptor blockers improved endothelium-dependent vasodilation.108 The vasodilating 
properties of endothelin-1 receptor blockers might explain the beneficial effects on BP of 
bosentan, a non-selective ET-1 receptor blocker. Krum et al have shown that 4 weeks of 
treatment with bosentan reduced blood pressure as effectively as enalapril.137 Moreover, the 
favourable effect of treatment with bosentan on blood pressure occurred without reflexive 
neurohormonal activation, which may suggest a more targeted effect of this drug on 
endothelial ET-1. Atrasentan (a selective ET-1 subtype A receptor antagonist) has also been 
shown to improve coronary endothelial function.138 
 
Future Directions and Conclusions 
There is little doubt that endothelial dysfunction and hypertension co-exist, however many 
questions still need to be answered. While we know that reducing blood pressure improves 
prognosis, there is still a lot doubt as to the incremental prognostic value of measurement of 
endothelial function. If this is established, we then need to find therapies that can improve 
endothelial function and whether this can translate to a longer-term prognostic benefit. The 
measurement of endothelial function itself needs to be standardized further and validated so 
that it can be used as both an endpoint in prognostic studies and as a marker in general 
clinical use. In common with much of the literature in this area, we have used the term 
“endothelial dysfunction” to refer exclusively to the vasodilatory properties of the 
endothelium, however it has numerous other functions, many of which could be quantified 
such as platelet aggregation and inflammation, and might have prognostic significance and 
may offer new therapeutic targets. 
 
Endothelial dysfunction is associated with hypertension and its presence correlates with target 
organ damage. Furthermore, endothelial dysfunction may be both a cause and a consequence 
of hypertension. In this review, we have discussed the pathways by which endothelial 
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dysfunction may occur and the clinical evidence of its importance. Finally, we discussed the 
evidence looking at reversal of endothelial function, both by non-pharmacological methods 
and antihypertensive medications and therapies more directly targeted at the endothelium. 
Antihypertensive drug treatment improves and in some cases reverses endothelial dysfunction 
but this appear to depend very much on drug class and the vascular territories studied. 
Although calcium channel blockers, ACE-I, and ARBs seem to outperform beta-blockers 
(with the exception of nebivolol) and diuretics in terms of improving endothelial dysfunction, 
they do not seem to produce a greater antihypertensive effect. Most importantly, there is still 
some doubt within the scientific community as to whether the improvement in endothelial 
function is translated into long-term prognostic benefit.  
 
In conclusion, although endothelial dysfunction is a conceptually attractive therapeutic target 
in hypertension, at this point in time, we lack convincing data that using endothelial 
dysfunction to guide our treatment would produce any better outcomes than using blood 
pressure targets to guide our treatment. This situation may change in the near future as more 
trials are conducted in this area. 
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